Castle Biosciences, Inc. announced that new data supporting its portfolio of skin cancer gene expression profile (GEP) tests will be showcased in one late-breaking oral presentation and three ePosters at the 2023 American Academy of Dermatology (AAD) Annual Meeting, being held March 17-21 in New Orleans. Following are details for the four abstracts that were accepted at AAD.Abstract content for the ePosters will be available in the online viewing portal beginning the first day of the meeting and on-site using the computers at theoster Exhibit Presentation Center. They will also be published online via the JAAD supplement in Fall 2023.

DecisionDx(R)-SCC Late-breaking oral presentation title: The 40-gene expression profile (40-GEP) continues to demonstrate independent metastatic risk stratification and improved accuracy in risk assessment in a novel cohort of cutaneous squamous cell carcinoma (cSCC) patients with one or more risk factors Presenter and Lead Author: Ashley Wysong, M.D., M.S., Department of Dermatology, University of Nebraska Medical Center Date: March 18, 2023 Time: 3:40-3:50 p.m. Central time Location: New Orleans Ernest N. Morial Convention Center, Theater B ePoster title: Clinicians' use of the 40-gene expression profile (40-GEP) test for high-risk cutaneous squamous cell carcinoma (SCC) patients is consistent with intended use parameters Lead Author: Gaurav Singh, M.D., Milwaukee Abstract Number: 44006 DecisionDx(R)-Melanoma ePoster title: The 31-gene expression profile test for cutaneous melanoma identifies patients with stage IB-IIA disease who have recurrence risk similar to that of stage IIB-IIC disease Lead Author: Abel Jarell, M.D., Northeast Dermatology Associates, P.C., Portsmouth, New Hampshire Abstract Number: 43858 MyPath(R) Melanoma ePoster title: Diagnostic discordance among histopathological reviewers for difficult-to-diagnose melanocytic lesions Lead Author: Matthew Goldberg, M.D., Castle Biosciences and Icahn School of Medicine at Mount Sinai, New York Abstract Number: 42072.